

CORE LABORATORIES N V  
Form DEFA14A  
March 20, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities  
Exchange Act of 1934 (Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Core Laboratories N.V.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



\*\*\* Exercise Your Right to Vote \*\*\*

IMPORTANT NOTICE Regarding the Availability of Proxy Materials  
for the Shareholder Meeting To Be Held on May 23, 2019

---

Meeting Information

CORE LABORATORIES N.V. Meeting Type: Annual Meeting  
For holders as of: April 25, 2019  
Date: May 23, 2019 Time: 9:00 am CEST  
Location: Hotel Sofitel Legend the Grand Amsterdam  
Oudezijds Voorburgwal 197, 1012 EX  
Amsterdam, The Netherlands

CORE

LABORATORIES  
N.V.

You are receiving this communication because you hold shares in the above named company.

C/O CORE

LABORATORIES LP  
6316 WINDFERN  
ROAD  
HOUSTON, TX  
77040

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

The proxy materials are available at [www.proxydocs.com/clb](http://www.proxydocs.com/clb). If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy (as instructed on the reverse side) on or before May 9, 2019 to facilitate timely delivery.

See the reverse side of this notice to obtain proxy materials and voting instructions.

---

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:  
NOTICE AND PROXY STATEMENT                      ANNUAL REPORT

How to View

Online:

Have the information that is printed in the box marked by the arrow à 

XXXX	XXXX	(located on the following
XXXX		page) and

  
visit: [www.proxydocs.com/clb](http://www.proxydocs.com/clb).

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

- 1) BY INTERNET: The proxy materials are available at [www.proxydocs.com/clb](http://www.proxydocs.com/clb).
- 2) BY TELEPHONE: 1-800-579-1639
- 3) BY E-MAIL\*: [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com)

\* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow à 

XXXX	XXXX	XXXX	(located on the following page) in the subject
			line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 9, 2019 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

**Vote In Person:** Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. To obtain directions to the meeting, call 713 - 328 - 2104.

**Vote By Internet:** To vote now by Internet, go to [www.proxyvote.com](http://www.proxyvote.com). Have the information that is printed in the box marked by the arrow à 

XXXX	XXXX	XXXX
------	------	------

 available and follow the instructions.

**Vote By Mail:** You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.



The Board of Supervisory Directors recommends that you vote FOR the following:

To re-elect two Class II Supervisory Directors, Martha Z. Carnes and Michael Straughen, and to elect one new Class II Supervisory Director, Gregory Barnett, to  
1. serve until our annual meeting in 2022 under the terms and conditions described within the proxy statement and until their successors shall have been duly elected and qualified;

Nominees:

- 1a) Martha Z. Carnes
- 1b) Michael Straughen
- 1c) Gregory B. Barnett

The Board of Supervisory Directors recommends you vote FOR the following proposals:

- 2. To appoint KPMG, including its U.S. and Dutch affiliates, (collectively, "KPMG") as Core Laboratories N.V.'s (the "Company") independent registered public accountants for the year ending December 31, 2019.
- 6. To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until

November 23,  
2020.

To confirm and adopt  
our Dutch Statutory  
Annual Accounts in the  
English language for the  
fiscal year ended  
3. December 31, 2018,  
following a discussion  
of our Dutch Report of  
the Management Board  
for that same period.

To approve  
and resolve the  
extension of  
the authority to  
limit or  
exclude the  
preemptive  
rights of the  
holders of our  
common  
7. shares and/or  
preference  
shares up to a  
maximum of  
10% of  
outstanding  
shares per  
annum until  
November 23,  
2020.

4. To approve and resolve  
the cancellation of our  
repurchased shares held  
at 12:01 a.m. CEST on  
May 23, 2019.

8. To approve, on  
an advisory  
basis, the  
compensation  
philosophy,  
policies and  
procedures  
described in  
the section  
entitled  
Compensation  
Discussion and  
Analysis and  
the  
compensation  
of Core  
Laboratories  
N.V.'s named  
executive  
officers as  
disclosed  
pursuant to the  
United States  
Securities and  
Exchange

Commission's  
compensation  
disclosure  
rules,  
including the  
compensation  
tables.

5. To approve and resolve  
the extension of the  
existing authority to  
repurchase up to 10% of  
our issued share capital  
from time to time for an  
18-month period, until  
November 23, 2020, and  
such repurchased shares  
may be used for any  
legal purpose.

NOTE: Such  
other business  
as may  
properly come  
before the  
annual  
meeting or any  
adjournment  
thereof shall  
be voted in  
accordance  
with the  
discretion of  
the attorneys  
and proxies  
appointed  
hereby.